SO YOU DRIVE to the local park for your morning walk, drive and take a Metro to your office, where you grab the lift to the third floor, and then you repeat the commute in the evening. If you have to queue up for an autorickshaw, you crib about last-mile connectivity to your doorstep, instead of walking that mile.
That’s rising urbanisation and sedentary lifestyles for you. The bane of modern India. But they are a boon for pharmaceutical companies such as Eli Lilly & Co, whose 146-year history has been powered by a list of firsts: the first treatment for pernicious anaemia, the first mass-produced antibiotic, the mass-produced Salk polio vaccine, human insulin, and pills for clinical depression and schizophrenia, among others.
Lilly is now betting that its drugs for obesity and diabetes will power its revenues into a higher trajectory. Especially as obesity and diabetes are like the proverbial chicken and egg situation: which came first? Lilly’s portfolio also has your heart covered (obesity and diabetes can get your heart).
RESPONDING TO THE DUAL CRISIS
US-based Lilly is no stranger to India. In 1993, it set up a unit to bring its treatments for diabetes, a range of cancers, osteoporosis, rheumatoid arthritis, men’s health, and growth hormone deficiency.
Now, it aims to bring to India its hugely successful drug Mounjaro that is used to treat Type 2 diabetes and as an anti-obesity drug for adults. In the US, Lilly has launched two different brands: Zepbound for obesity; and Mounjaro for Type 2 diabetes. In both, the active ingredient is tirzepatide. Mounjaro’s revenue exceeded $5 billion in 2023, its first full year on the market.
According to the FDA, approximately 70% of American adults are obese or overweight, and many of those overweight have a weight-related condition.
This story is from the March 31, 2024 edition of Business Today India.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 31, 2024 edition of Business Today India.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
"Inaction is worse than mistakes"
What was the problem you were grappling with?
TEEING OFF WITH TITANS
BUSINESS TODAY GOLF RESUMES ITS STORIED JOURNEY WITH THE 2024-25 SEASON OPENER IN DELHI-NCR. THERE ARE SIX MORE CITIES TO COME
AI FOOT FORWARD
THE WHO'S WHO OF THE AI WORLD GATHERED AT THE TAJ MAHAL PALACE IN MUMBAI TO DELIBERATE THE TRANSFORMATIVE IMPACT OF AI ON INNOVATION, INDUSTRIES, AND EVERYDAY LIFE.
Decolonising the Walls
ART START-UP MAAZI MERCHANT IS ON A MISSION TO BRING INDIA'S FORGOTTEN ART BACK HOME
"I'm bringing Kotak under one narrative, one strategy, one umbrella”
Ashok Vaswani is a global banker who spent most of his career overseas at institutions like Citi Group and Barclays, among others.
CHOOSING THE CHAMPIONS
The insights and methodology behind the BT-KPMG India's Best Banks and NBFCs Survey 2023-24.
'INDIA IS AT AN EXTREMELY SWEET SPOT'
The jury members of the BT-KPMG Survey of India's Best Banks and NBFCs discuss developments in the banking sector and more
FROM CRISIS TO TRIUMPH
Dinesh Kumar Khara stewarded SBI through multiple challenges during his tenure, while ensuring that profits tripled, productivity soared, and the bank consolidated its global standing
AT A CROSSROADS
BANKS ARE FACING CHALLENGES ON BOTH SIDES OF THE BALANCE SHEET-ASSETS AS WELL AS LIABILITIES-WHICH ARE PUTTING PRESSURE ON MARGINS.
EXPANSIVE VISION
Bajaj Finance, an outlier in terms of digitisation, faces stiff competition. But it continues to expand its reach
